The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

Inclusion Criteria

• •1. Age 18 years or older at signing of informed consent
• •2. Diagnosis of Type 2 Diabetes minimum 180 days before the day of screening
• •3. Hemoglobin A1c between 7-9% and measured by local lab at screening
• •4. On daily basal insulin for at least 90 days before inclusion into the study
• •5. Stable dose of oral and injectable (other than insulin) antidiabetic medications for 90 days prior inclusion. Acceptable medications include:
• •1. Metformin
• •2. Sulfonylureas
• •3. Meglitinides (glinides)
• •4. Dipeptidyl peptidase 4 (DPP-4) inhibitors
• •5. Sodium glucose co-transporter 2 (SGLT2) inhibitors
• •6. Thiazolidinediones
• •7. Alpha-glucosidase inhibitors
• •8. Oral combination products (for the allowed individual oral anti-diabetic drugs)
• •9. Oral or injectable Glucagon-like peptide-1 (GLP-1) Receptor Agonists (RAs)
• •10. If on sulfonylureas or glinides, willingness to reduce dose by 50%
• •8. Known skin reactions to CGM adhesives
• •9. Current/prior use of CGM within 30 days of the screening visit
• •10. Any planned surgery or procedures where basal insulin would be decreased or held in anticipation